The pathophysiology of Alzheimer’s disease (AD) is a complex phenomenon which mediating through Aβ plaque formation and neurofibrillary tangles. Since, last few decades preclinical and clinical research evidences strengthen the elucidation of underlying causes in disease progression. The ongoing studies are mainly focused to screen the potential clinical candidates which turndown the neurodegeneration or delaying in AD progression. Considering the complicated etiopathogenesis of AD, the therapies which target the multiple molecular pathways of AD is required to potentiate the treatment and which in turn regulates the AD related complications. Diosgenin (DG), a natural steroidal saponin which has proven for an antioxidant, neuroprotective effects, and Pioglitazone is a peroxisome proliferator-activated receptor-γ agonist that has been found to be effective in treating several neuropathies. DG and Pioglitazone combination may be a successful novel approach in treating AD and other neurodegenerative disorders; in the present study, we were targeted the neuro-inflammatory pathways with Pioglitazone and DG to evaluate the neuroprotective potential especially in AD like condition. Overall, the research findings revealed the possible therapeutic benefits with novel combination and it was notably down-regulated the cytokine storm and Aβ plaque formation.
Key words: Alzheimer’s disease, beta amyloid proteins, PPAR-γ, neuroinflammation
|
